News & Updates
Filter by Specialty:

Can rosuvastatin protect against chemo-induced cardiotoxicity in HER2+ breast cancer?
Use of rosuvastatin is associated with a significantly lower decline in left ventricular ejection fraction (LVEF) and lower serum levels of cardiotoxicity-associated biomarkers in newly diagnosed HER2-positive breast cancer patients treated with anthracycline-based chemotherapy followed by trastuzumab, according to the results of a prospective, randomized, controlled, parallel study.
Can rosuvastatin protect against chemo-induced cardiotoxicity in HER2+ breast cancer?
22 Jul 2024
Over-the-counter supplement touted for improving walking distance in PAD
Nicotinamide riboside supplements show a signal of benefit for helping patients with lower extremity peripheral arterial disease (PAD) walk more
Over-the-counter supplement touted for improving walking distance in PAD
21 Jul 2024
Wearables on par with conventional tools for cardiac monitoring
Electrocardiogram (ECG)- and photoplethysmography (PPG)-based wearable devices demonstrate effectiveness for paroxysmal atrial fibrillation (AF) detection following cryptogenic stroke or embolic stroke of undetermined source (ESUS) similar to that of conventional management, results of a Singapore study have shown.
Wearables on par with conventional tools for cardiac monitoring
18 Jul 2024
Reduced kidney function after stroke ups risk of recurrence, dementia
Patients with declining kidney function following a cerebrovascular event are at increased risk of major adverse cardiovascular events (MACE), dementia, and mortality at 2 years, according to a study. However, a higher risk of death is also noted for those with a large increase in kidney function.